Subclinical Cardiac Microdamage, Motor Severity, and Cognition in Parkinson's Disease

Mov Disord. 2020 Oct;35(10):1863-1868. doi: 10.1002/mds.28129. Epub 2020 Jun 17.

Abstract

Background: We assessed if cardiac blood markers are associated with motor and cognitive function in patients with Parkinson's disease (PD).

Methods: High-sensitivity troponin I and N-terminal pro-B-type natriuretic peptide (NT-proBNP) were evaluated in 285 PD patients. Furthermore, N-terminal pro-B-type natriuretic peptide levels were analyzed in 570 age, sex and cardiovascular risk factor matched healthy controls. Motor (UPDRS, Hoehn &Yahr) and cognitive function (Montreal Cognitive Assessemtn) were assessed at baseline in all 285 patients and after 1 year in 101 patients.

Results: N-terminal pro-B-type natriuretic peptide were significantly increased in 285 PD patients compared with 570 matched healthy controls. In PD patients, increased high-sensitivity troponin I and N-terminal pro-B-type natriuretic peptide levels were associated with worse motor function at baseline and also with motor decline after 1 year. N-terminal pro-B-type natriuretic peptide and high-sensitivity troponin I were inversely associated with cognitive function at baseline only in unadjusted models.

Conclusions: Subclinical cardiac microdamage is associated with motor severity in PD patients. © 2020 The Authors. Movement Disorders published by Wiley Periodicals, Inc. on behalf of International Parkinson and Movement Disorder Society.

Keywords: Montreal cognitive assessment; N-terminal pro-B-type natriuretic peptide; high-sensitivity troponin I.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Biomarkers
  • Cognition
  • Humans
  • Natriuretic Peptide, Brain
  • Parkinson Disease* / complications
  • Peptide Fragments

Substances

  • Biomarkers
  • Peptide Fragments
  • Natriuretic Peptide, Brain